Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 7, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it’s oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 - 22, 2025 virtually and at the Georgia World Congress Center in Atlanta, Georgia. Details of the presentations are as follows: Zelicapavir: Rapid-Fire Presentation Title: “Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age” Date: Monday, October 20, 2025 Time: 12:35 PM - 12:40 PM EDT Presentation Number: 135 Session: Pediatric Respiratory Virus Location: Poster Hall B4-B5 - Arena 2 Presenter: Dr. Christopher E. Harris Poster Title: “Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age” Date: Monday, October 20, 2025 Time: 12:15 PM - 1:30 PM EDT Poster Number: 523 Session: Pediatric Viral Studies Location: Poster Hall B4-B5 Presenter: Dr. Christopher E. Harris EDP-323: Oral Presentation Presentation Title: “EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower Respiratory Tract RSV Symptoms and Viral Load After Human Viral Challenge” Date: Monday, October 20, 2025 Time: 4:15 PM - 4:27 PM EDT Presentation Number: 235 Session: New Anti-Infective Agents Location: B213-B214 Presenter: Dr. John P. DeVincenzo Poster Presentation Poster Title: “Post-Exposure Prophylaxis (PEP) of Respiratory Syncytial Virus (RSV) Infection After High-Inoculum RSV Human Challenge: Analysis of a Randomized Double-Blind, Placebo-Controlled Trial of EDP-323, an Oral, Non-Nucleoside Polymerase Inhibitor Antiviral” Date: Wednesday, October 22, 2025 Time: 12:15 PM - 1:30 PM EDT Poster Number: 2181 Session: Virology Location: Poster Hall B4-B5 Presenter: Dr. John P. DeVincenzo Posters will be available to view on the conference platform during the conference and on the Company’s website here after presentations. Further information about IDWeek™ 2025 can be found here. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. View source version on businesswire.com: https://www.businesswire.com/news/home/20251007604798/en/ Media and Investors Contact Jennifer Viera 617-744-3848 [email protected] Source: Enanta Pharmaceuticals, Inc. Print Page Print Page Email Alerts Email Alerts RSS Feeds RSS Feeds Contact IR Contact IR ©2026 Enanta Pharmaceuticals, Inc. ENANTA PHARMACEUTICALS and accompanying logos are trademarks or registered trademarks of Enanta Pharmaceuticals, Inc. Explore About Pipeline Science Patients Careers Collaborations Investors Contact Us Contact Enanta Pharmaceuticals, Inc. Headquarters 4 Kingsbury Avenue Watertown, MA 02472 (617) 607-0800 [email protected] Legal Privacy Policy Terms of Use Twitter Linkedin MENU About About Us Management Team Board of Directors Timeline Pipeline Overview Hepatitis C Virus Hepatitis B Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology Science Overview Publications Patients Overview Clinical Trials Expanded Access Policy Resources Careers Join Us Culture Core Values Testimonials Benefits Collaborations Partnering Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feeds Email Alerts Contact Us

The release as fetched from its publisher. enanta.com ↗